Abstract Monocyte chemoattractant protein-1 (MCP-1) seems to be involved in the pathogenesis of multiple sclerosis (MS). We found that in unstimulated (PHA−) and PHA-stimulated (PHA+) peripheral blood mononuclear cells (PBMC), MCP-1 and TNFα levels are higher in stable untreated MS patients. Interferon gamma (IFNγ) is higher in relapsing patients in PHA− cultures and in stable patients in PHA+ cultures. Chronic IFNβ-1b treatment down-regulates TNFα, IFNγ and MCP-1 production except for TNFα in relapsing patients. IFNβ-1b, in vitro, increases MCP-1, TNFα and IFNγ spontaneous production in all patients. Multivariate analysis suggests that MCP-1 production is dependent from clinical status and not from TNFα and IFNγ production. Logistic regression analysis shows that MCP-1 production is significantly modified by treatment. Further studies are needed to clarify the role of MCP-1 in MS. Keywords Multiple sclerosis; MCP-1; TNFα; IFNγ; IFNβ; Peripheral blood mononuclear cells

Interferon β1b modulates MCP-1 expression and production in relapsing-remitting multiple sclerosis

IARLORI, Carla;REALE, Marcella;DE LUCA, Giovanna;DI IORIO, Angelo;FELICIANI, Claudio;TULLI, Antonio;CONTI, Pio;GAMBI, Domenico;
2002-01-01

Abstract

Abstract Monocyte chemoattractant protein-1 (MCP-1) seems to be involved in the pathogenesis of multiple sclerosis (MS). We found that in unstimulated (PHA−) and PHA-stimulated (PHA+) peripheral blood mononuclear cells (PBMC), MCP-1 and TNFα levels are higher in stable untreated MS patients. Interferon gamma (IFNγ) is higher in relapsing patients in PHA− cultures and in stable patients in PHA+ cultures. Chronic IFNβ-1b treatment down-regulates TNFα, IFNγ and MCP-1 production except for TNFα in relapsing patients. IFNβ-1b, in vitro, increases MCP-1, TNFα and IFNγ spontaneous production in all patients. Multivariate analysis suggests that MCP-1 production is dependent from clinical status and not from TNFα and IFNγ production. Logistic regression analysis shows that MCP-1 production is significantly modified by treatment. Further studies are needed to clarify the role of MCP-1 in MS. Keywords Multiple sclerosis; MCP-1; TNFα; IFNγ; IFNβ; Peripheral blood mononuclear cells
File in questo prodotto:
File Dimensione Formato  
Iarlori J Neuroimmunol 2002.pdf

Solo gestori archivio

Tipologia: PDF editoriale
Dimensione 265.64 kB
Formato Adobe PDF
265.64 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11564/215592
Citazioni
  • ???jsp.display-item.citation.pmc??? 7
  • Scopus 26
  • ???jsp.display-item.citation.isi??? 24
social impact